Autoimmune events during interferon beta-1b treatment for multiple sclerosis
| Autor: | M.A Biava, M. R. Bongioanni, Giorgio Maria Saracco, L Giorda, A. Oggero, A. Ricci, Luca Durelli, Bruno Bergamasco, P.C. Brossa, E Gentile, E. Verdun, G. Aimo, R Pagni, Eugenia Rota, B. Ferrero, Marilena Durazzo, G. Isoardo |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Multiple Sclerosis Time Factors Thyroid Function Tests Thyroid function tests Autoimmune Diseases Radioligand Assay Liver Function Tests Recurrence medicine Humans Prospective Studies Autoantibodies medicine.diagnostic_test business.industry Thyroid disease Interferon beta-1b Thyroid Autoantibody Interferon beta-1a Interferon-beta Middle Aged medicine.disease Recombinant Proteins medicine.anatomical_structure Neurology Immunology Female Neurology (clinical) Liver function business Liver function tests medicine.drug Follow-Up Studies |
| Zdroj: | Journal of the neurological sciences. 162(1) |
| ISSN: | 0022-510X |
| Popis: | Autoimmune events, although rarely reported during interferon beta-1b (IFNB) treatment of relapsing-remitting (RR) multiple sclerosis (MS), may be more frequent than expected due to the many immunologic abnormalities associated with this disease. We report the prospective two-year follow-up of autoimmune events in 40 RR MS patients treated with IFNB and in 21 untreated MS controls. Thyroid and liver function and serum level of 12 autoantibodies (autoAbs) against organ- (thyroid, gastric, pancreatic) and non-organ-specific antigens were serially monitored. In contrast to control patients, autoAbs (anti-nuclear, -smooth muscle or -thyroid antigens) were detected in 13 IFNB-treated patients, and these were associated with thyroid or liver function alteration in many cases. Persistent autoimmune thyroid dysfunction occurred in three IFNB-treated patients, all of whom were women with a familial history of thyroid disease or baseline anti-thyroid autoAb positivity. For improvement of the MS relapse rate, thyroid dysfunction was adequately treated without stopping IFNB. Liver function alteration (17 IFNB-treated patients, associated with non-organ-specific autoAbs in four) was transient and did not require IFNB treatment to be stopped, with the exception of one patient who was already suffering from a drug-induced hepatopathy at baseline. During the IFNB treatment of MS, several autoimmune events may occur, indicating that thyroid and liver function and autoAbs must be carefully monitored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect